• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SWK Holdings Provides Portfolio Update

    10/17/24 4:15:00 PM ET
    $BTCY
    $DERM
    $ELUT
    $ETON
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BTCY alert in real time by email

    Company Announces Q3 Earnings and Conference Call Dates

    DALLAS, TX / ACCESSWIRE / October 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, provided today a portfolio update and announced the anticipated date of the third quarter earnings and conference call schedule.

    The Company intends to issue their third quarter financials after market close on November 14, 2024, and will host a conference call at 9:00 a.m. Central Time on November 15, 2024, to discuss the company's financial results for the quarter. Call details will be available in the quarterly results news release.

    Originations and Repayments

    In September, SWK expanded its existing credit facility with Eton by $25.7M to $30.0M. The extension will support Eton's acquisition of Increlex, which is expected to close near year-end 2024.

    In September, Epica International, Inc. repaid the outstanding term loan principal balance of $8.3M as well as accrued interest and exit fee. SWK continues to hold an equity interest in Epica.

    Portfolio Company Updates

    4WEB Medical

    4WEB Medical is a privately held medical device company that develops orthopedic implants that utilize its proprietary Truss Implant Technology™.

    • Announced the appointment of Brad Niemann as President.

    AOTI, Inc.

    Advanced Oxygen Therapy, Inc. (AIM:AOTI) is a medical technology company that develops and markets proprietary wound care therapies.

    • Reported first half 2024 revenue of $26.3M, an increase of 26.4% versus the prior year's comparable period.

    • First half 2024 adjusted EBITDA was $3.4M compared with $0.7M during first half 2023, reflecting improvement across all business segments and operating leverage.

    • Announced US FDA 510(k) Clearance of NEXATM Negative Pressure Wound Therapy System to include use in the home care setting.

    Biotricity, Inc.

    Biotricity, Inc. (OTCQB:BTCY) is a medical technology company focused on delivering remote biometric monitoring solutions to the medical and consumer markets.

    • For quarter-ended June 30, 2024, revenues increased by 6% to $3.2M compared to $3.0M during the prior year's comparable quarter.

    • Gross margins improved to 73.8% during quarter-ended June 30, 2024, an increase from 63.5% in the same period last year, and 59.6% two years earlier.

    • Announced expectations for achieving profitability by the end of the current fiscal fourth quarter.

    • Announced a pilot program with a major hospital system that services over 800k individuals.

    Elutia

    Elutia Inc. (NASDAQ:ELUT) is a biologics company with a portfolio of regenerative products aimed at improving compatibility between medical devices and the patients they treat.

    • For the quarter ended June 30, 2024, reported CanGaroo and SimpliDerm net sales growth of 19% and 7%, respectively, over prior year's comparable quarter.

    • In August, raised gross proceeds of approximately $15.7M from the exercise of outstanding warrants, resulting in cumulative year-to-date gross equity proceeds of $29.0M.

    Eton Pharmaceuticals, Inc.

    Eton (NASDAQ:ETON) is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases.

    • Reported revenue for the quarter ended June 30, 2024, of $9.1M, 40% year-over-year growth and the 14th consecutive quarter of sequential sales growth.

    • Reported Cash Flow from Operations of $1.3M (including the payment of a one-time $2.0M NDA filing fee for ET-400) for the quarter.

    • In July 2024, announced FDA acceptance of its New Drug Application ("NDA") for ET-400, Eton's proprietary, patented room temperature stable formulation of oral hydrocortisone solution. ET-400 was assigned a February 28, 2025, PDUFA date.

    • In October, Eton announced it had entered into an asset purchase agreement to acquire Increlex from Ipsen. The transaction is expected to close near year-end 2024.

    Journey Medical Corporation

    Journey Medical Corporation (NASDAQ:DERM) is a commercial-stage pharmaceutical company focused on commercializing FDA-approved, prescription dermatology products.

    • Total revenues for the second quarter ended June 30, 2024, were $14.9M, a 14% increase from the $13.0M reported in the first quarter of 2024.

    • Adjusted EBITDA of $0.3M for the second quarter ended June 30, 2024, compared to Adjusted EBITDA of $(0.6M) for the second quarter of 2023.

    MolecuLight, Inc.

    MolecuLight Inc. is a leader in point-of-care fluorescence imaging that locates and detects elevated, pathogenic bacterial loads in and around wounds.

    • In August, announced the closing of a $11.7 million Series C financing round led by new investors Export Development Canada (EDC), Prosegur, and Azahar. Existing investors also participated in the round, demonstrating continued confidence in the company's growth trajectory.

    Shield Therapeutics plc (LSE:STX)

    Shield (LSE:STX) is a commercial-stage specialty pharmaceutical company focused on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol).

    • For the first half 2024, total Accrufer® prescriptions totaled 65.2k, up 160% compared with the prior year's comparable period

    • Average first half 2024 Accrufer® net selling price of $158 per prescription, a 33% increase versus the first half 2023. The second quarter 2024 average net selling price per prescription was $171.

    • First half 2024 total revenue of $12.1M, up 320% compared with the prior year's comparable period

    • Completed a $5.7M monetization agreement with AOP Health International Management AG.

    • Announced approval of Accrufer® by Health Canada via Kye Pharmaceuticals ("Kye"), Shield's Canadian commercialization partner. Based on Shield's collaboration agreement with Kye, it will be the potential beneficiary of certain future milestone payments and double-digit royalties on net sales of Accrufer®.

    • Announced the results of a Phase 3 pediatric clinical trial (FORTIS/ST10-01-305) that confirmed the efficacy, safety, and tolerability of its oral liquid suspension for children with iron deficiency anemia. This trial is the final study in the development program, and the data will be used to support a filing with the FDA for a pediatric indication in children older than 1 month in 1H25.

    About SWK Holdings Corporation

    SWK Holdings Corporation is a life science focused specialty finance company partnering with small- and mid-sized commercial-stage healthcare companies. SWK provides non-dilutive financing to fuel the development and commercialization of lifesaving and life-enhancing medical technologies and products. SWK's unique financing structures provide flexible financing solutions at an attractive cost of capital to create long-term value for all SWK stakeholders. SWK's solutions include structured debt, traditional royalty monetization, synthetic royalty transactions, and asset purchases typically ranging in size from $5.0 million to $25.0 million.

    SWK also owns Enteris BioPharma, a clinical development and manufacturing organization providing development services to pharmaceutical partners as well as innovative formulation solutions built around its proprietary oral drug delivery technologies, the Peptelligence® platform. Additional information on the life science finance market is available on the Company's website at www.swkhold.com.

    Safe Harbor for Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Because these statements reflect SWK's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption "Risk Factors" and elsewhere in SWK's Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein, could affect the Company's future financial results and could cause actual results to differ materially from those expressed in such forward-looking statements. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause the Company's actual results to differ materially from expected and historical results. You should not place undue reliance on any forward-looking statements, which speak only as of the date they are made. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

    For more information, please contact:

    Investor Relations and Media
    Ira M. Gostin
    [email protected]
    775-381-0213

    SOURCE: SWK Holdings Corp.



    View the original press release on accesswire.com

    Get the next $BTCY alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Q&A

    New
    • When is the anticipated date for SWK Holdings Corporation's third quarter financial results release?

      SWK Holdings Corporation plans to release its Q3 earnings on November 14, 2024, after market close.

    • What time and date is the conference call scheduled to discuss the Q3 financial results?

      The conference call to discuss Q3 financial results will be held at 9:00 a.m. Central Time on November 15, 2024.

    • How much did SWK expand its credit facility with Eton and what is the new total amount?

      SWK expanded its existing credit facility with Eton by $25.7 million, increasing it to a total of $30.0 million.

    • What significant leadership change has occurred at 4WEB Medical?

      4WEB Medical appointed Brad Niemann as President, which reflects a change in leadership at the company.

    • What revenue growth did Eton Pharmaceuticals report for the quarter ended June 30, 2024?

      Eton Pharmaceuticals reported a revenue of $9.1M for the quarter ended June 30, 2024, marking a 40% year-over-year growth.

    Recent Analyst Ratings for
    $BTCY
    $DERM
    $ELUT
    $ETON

    CompanyDatePrice TargetRatingAnalyst
    Eton Pharmaceuticals Inc.
    $ETON
    1/23/2025$17.00 → $33.00Buy
    H.C. Wainwright
    Eton Pharmaceuticals Inc.
    $ETON
    1/10/2025$21.00Buy
    B. Riley Securities
    Eton Pharmaceuticals Inc.
    $ETON
    1/6/2025$15.00 → $17.00Buy
    H.C. Wainwright
    Eton Pharmaceuticals Inc.
    $ETON
    9/4/2024$9.00Buy
    H.C. Wainwright
    Journey Medical Corporation
    $DERM
    8/22/2024$9.00Buy
    Rodman & Renshaw
    Journey Medical Corporation
    $DERM
    6/28/2024$11.00Buy
    ROTH MKM
    Eton Pharmaceuticals Inc.
    $ETON
    5/6/2024$8.00Buy
    Craig Hallum
    Biotricity Inc.
    $BTCY
    11/20/2023Buy → Neutral
    H.C. Wainwright
    More analyst ratings

    $BTCY
    $DERM
    $ELUT
    $ETON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Toledano Miranda Jayne was granted 7,173 shares, increasing direct ownership by 9% to 88,618 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      7/7/25 9:50:54 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Rosenwald Lindsay A Md was granted 7,173 shares, increasing direct ownership by 5% to 161,146 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      7/7/25 9:50:05 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Pearce Michael Cooper was granted 7,173 shares, increasing direct ownership by 24% to 37,173 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      7/7/25 9:48:55 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BTCY
    $DERM
    $ELUT
    $ETON
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Biotricity Delivers Strong Fiscal Year 2025 Results with Revenue Growth, Continued Margin Improvement, and Reduced Operating Expenses, Putting Profitability within Reach

      FY25 revenue up 14.3% YOYFY25 margins improvement of 8.9% to 76.6%, from 69.3% in the prior year; Q4-FY25 margins improved to 80.4% as margin expansion forecasted to continueFY25 operating expenses lower by 24.5% YOYNegative EBITDA reduced by $5.7 million to $3.2 million – an improvement of 63.9%Positive Adjusted EBITDA of $438,260 in the fourth quarter of FY25 – first time in Company's history, highlighting Company's ability to achieve breakeven and EBITDA positive in the early part of its FY26 REDWOOD CITY, CA, July 17, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company that offers innovative diagnostic, chroni

      7/17/25 9:33:00 AM ET
      $BTCY
      Medical/Dental Instruments
      Health Care
    • Biotricity to Host Fiscal 2025 Fourth Quarter Financial Results and Business Update Call on July 18th

      Company to announce improvements in Margins, Operational Efficiency, and a shift to positive Adjusted EBITDA REDWOOD CITY, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, will host its Fiscal 2025 Fourth Quarter Financial Results and Business Update Call on July 18, 2025. The Company announces the best financial performance thus far and a shift to positive adjusted EBITDA. Biotricity's Founder and CEO, Dr. Waqaas Al-Siddiq, and CFO, John Ayanoglou, will deliver remarks followed by a Q

      7/15/25 5:05:00 PM ET
      $BTCY
      Medical/Dental Instruments
      Health Care
    • Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™

      Payer coverage for Emrosi™ now available for 65% of commercial lives, up from 29% in May 2025 Expanding payer coverage supports the adoption of Emrosi as prescription demand continues to increase SCOTTSDALE, Ariz., July 14, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company", "we", or "our"), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that 65% of the 187 million commercial lives in the United States now have pharmacy benefit coverage for Emrosi™ (40 mg Minocycline Hydrochloride Modifi

      7/14/25 8:30:07 AM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BTCY
    $DERM
    $ELUT
    $ETON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright reiterated coverage on Eton Pharmaceuticals with a new price target

      H.C. Wainwright reiterated coverage of Eton Pharmaceuticals with a rating of Buy and set a new price target of $33.00 from $17.00 previously

      1/23/25 9:02:14 AM ET
      $ETON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • B. Riley Securities initiated coverage on Eton Pharmaceuticals with a new price target

      B. Riley Securities initiated coverage of Eton Pharmaceuticals with a rating of Buy and set a new price target of $21.00

      1/10/25 7:49:32 AM ET
      $ETON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright reiterated coverage on Eton Pharmaceuticals with a new price target

      H.C. Wainwright reiterated coverage of Eton Pharmaceuticals with a rating of Buy and set a new price target of $17.00 from $15.00 previously

      1/6/25 8:01:16 AM ET
      $ETON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BTCY
    $DERM
    $ELUT
    $ETON
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Opaleye Management Inc. bought $125,484 worth of shares (7,930 units at $15.82) (SEC Form 4)

      4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)

      6/12/25 4:32:51 PM ET
      $ETON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Highcape Capital, L.P. bought $1,050,000 worth of shares (420,000 units at $2.50) (SEC Form 4)

      4 - ELUTIA INC. (0001708527) (Issuer)

      3/13/25 4:30:13 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Highcape Capital, L.P. bought $1,050,000 worth of shares (420,000 units at $2.50) (SEC Form 4)

      4 - ELUTIA INC. (0001708527) (Issuer)

      3/13/25 4:28:27 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BTCY
    $DERM
    $ELUT
    $ETON
    Financials

    Live finance-specific insights

    See more
    • Biotricity Delivers Strong Fiscal Year 2025 Results with Revenue Growth, Continued Margin Improvement, and Reduced Operating Expenses, Putting Profitability within Reach

      FY25 revenue up 14.3% YOYFY25 margins improvement of 8.9% to 76.6%, from 69.3% in the prior year; Q4-FY25 margins improved to 80.4% as margin expansion forecasted to continueFY25 operating expenses lower by 24.5% YOYNegative EBITDA reduced by $5.7 million to $3.2 million – an improvement of 63.9%Positive Adjusted EBITDA of $438,260 in the fourth quarter of FY25 – first time in Company's history, highlighting Company's ability to achieve breakeven and EBITDA positive in the early part of its FY26 REDWOOD CITY, CA, July 17, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company that offers innovative diagnostic, chroni

      7/17/25 9:33:00 AM ET
      $BTCY
      Medical/Dental Instruments
      Health Care
    • Biotricity to Host Fiscal 2025 Fourth Quarter Financial Results and Business Update Call on July 18th

      Company to announce improvements in Margins, Operational Efficiency, and a shift to positive Adjusted EBITDA REDWOOD CITY, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, will host its Fiscal 2025 Fourth Quarter Financial Results and Business Update Call on July 18, 2025. The Company announces the best financial performance thus far and a shift to positive adjusted EBITDA. Biotricity's Founder and CEO, Dr. Waqaas Al-Siddiq, and CFO, John Ayanoglou, will deliver remarks followed by a Q

      7/15/25 5:05:00 PM ET
      $BTCY
      Medical/Dental Instruments
      Health Care
    • Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

      Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions Filled in Late March 2025 Phase 3 Clinical Trial Results for Emrosi Published in JAMA Dermatology Emrosi Now Included in Updated National Rosacea Society Treatment Algorithms Company to Hold Conference Call Today at 4:30 p.m. ET SCOTTSDALE, Ariz., May 14, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Admin

      5/14/25 4:01:35 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BTCY
    $DERM
    $ELUT
    $ETON
    SEC Filings

    See more
    • SWK Holdings Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement

      8-K - SWK Holdings Corp (0001089907) (Filer)

      7/17/25 5:04:20 PM ET
      $SWKH
      Diversified Financial Services
      Finance
    • SEC Form 10-K filed by Biotricity Inc.

      10-K - BIOTRICITY INC. (0001630113) (Filer)

      7/15/25 5:27:01 PM ET
      $BTCY
      Medical/Dental Instruments
      Health Care
    • Journey Medical Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Journey Medical Corp (0001867066) (Filer)

      7/14/25 4:50:28 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BTCY
    $DERM
    $ELUT
    $ETON
    Leadership Updates

    Live Leadership Updates

    See more
    • Journey Medical to Join Russell 2000® and Russell 3000® Indexes

      SCOTTSDALE, Ariz., June 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as a result of their 2025 annual Russell Index reconstitution. "We are very pleased to be included in the Russell 2000® and Russell 3000

      6/24/25 8:30:29 AM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

      SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, is pleased to announce the promotion of Ramsey Alloush, currently General Counsel, to the position of Chief Operating Officer ("COO"). Mr. Alloush will continue to also serve as the Company's General Counsel. Claude Maraoui, President and Chief Executive Officer of Journey Medical, commented, "Ramsey's promotion to COO reflects

      4/1/25 4:01:16 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

      January 22, 2025 Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announced today the appointment of Dr Gary A. Shangold as Chief Medical Officer with immediate effect. Commenting, Stephen Stamp, CEO and CFO of Biodexa said: "I am delighted to welcome Gary to the team. As Biodexa moves towards the later clinical stages including an upcoming global Phase 3 registrational study in FAP, it is essential we access specialists

      1/22/25 8:30:00 AM ET
      $BDRX
      $JNJ
      $SWKH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Diversified Financial Services
      Finance

    $BTCY
    $DERM
    $ELUT
    $ETON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Eton Pharmaceuticals Inc.

      SC 13G - Eton Pharmaceuticals, Inc. (0001710340) (Subject)

      12/9/24 4:04:43 PM ET
      $ETON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Journey Medical Corporation

      SC 13G - Journey Medical Corp (0001867066) (Subject)

      11/29/24 2:00:25 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Biotricity Inc.

      SC 13G/A - BIOTRICITY INC. (0001630113) (Subject)

      11/14/24 6:06:28 PM ET
      $BTCY
      Medical/Dental Instruments
      Health Care